George & Raghuram, thanks very much for the thorough interview and insight into some exciting biotech science. Ram, RE the timing of Neuralstem's SCI trial at UCSD, the CEO recently stated (here: http://www.neuralstem.com/neuralstem-ceo-blog/224-i-love-it-when-a-plan-comes-together
) "The first patient in this trial will hopefully be transplanted in September, and we hope to have all of the thoracic patients transplanted by the end of November, with a subsequent six-month observation period to collect data". This sounds to be much sooner
than you expected... does it change your 1 year target at all? Thoughts? Thanks in advance!
Latest Comments
Bring On The Orphans: Aegis Capital's Raghuram Selvaraju Lays Out A Winning Biotech Strategy